Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Chronic hepatitis C virus infection affects an estimated one hundred and seventy million
 people around the world with and approximate prevalence 0.2-2 % in the United State of
 America and European countries.
In Egypt, Chronic hepatitis C virus is a serious health problem where Chronic hepatitis C
 virus prevalence is very high.

 Chronic Chronic hepatitis C virus infection is associated with a high risk for liver-related
 mortality because of a variety of complications, which appear obviously in those patients
 with developing end-stage liver disease, including decompensated liver cirrhosis and
 hepatocellular carcinoma. Egypt had the highest burden of deaths from Chronic hepatitis C
 virus-associated hepatocellular carcinoma in the Arab world, around sixty three percentage of
 all Chronic hepatitis C virus-associated hepatocellular carcinoma deaths happened in Egypt.

 Poor response rates and poor tolerability were observed during treatment of chronic Chronic
 hepatitis C virus infection with pegylated interferon and ribavirin.

 Because Chronic hepatitis C virus does not incorporate into the human genome and must
 replicate to maintain infection, it should be potential to destroy the virus completely by
 blocking replication at one or more stages of the life cycle.

 In recent years, there has been a shift in treatment paradigm with the discovery and approval
 of agents that target specific proteins vital for hepatitis C replication. The Non Structural
 3/4A inhibitors simeprevir and paritaprevir, the NonStructural 5A inhibitors ombitasvir,
 ledipasvir, and daclatasvir, and the Non Structural 5B inhibitors sofosbuvir and dasabuvir
 have been approved and incorporated as first-line agents into the latest guidelines for
 Hepatitis C treatment. Used in combination, these agents produce higher rates of sustained
 virologic response and less adverse effects than historical options, along with limited rates
 of resistance.

 In previous studies ,haematological side effect of interferon and Ribavirin was reported in
 the form of reduction in Haemoglobin ,White Blood Cells and asymptomatic thrombocytopenia
 While SOF based combination therapy improved the liver function, anemia ,leucopenia and
 thrombocytopenia were detected especially after treatment with SOF,RBV and PegINF alpha .also
 significant improvement in the level of ALT and AST post treatment with either SOF and RBV or
 SOF ,RBV and INF were detected as compaired to baseline While no significant differences were
 detected on the level of total bilirubin or creatinine In our study we will assess and
 evaluate many biochemical and hematological findings upon new direct acting antiviral agents
 in Egyptian chronic hepatitis C virus patients
Inclusion Criteria:

 -  Our study proposed for all consented patients complaining from chronic Hepatitis C
 virus infection undergoing treatment with antiviral drugs is possible through certain
 indications or criteria as follow:

 -  Patients with chronic Hepatitis C virus who are candidates for Direct Acting Antiviral
 Therapy:

 -  Age is from 18 to 65 years.

 Exclusion Criteria:

 -  Those patients with chronic Hepatitis C virus infection are impossible or
 contraindicated to be treated with antiviral drugs as follow: - Geriatrics (> 65 years
 of age): - Pediatrics (< 18 years of age): - patients with known hypersensitivity to
 any of the components of the antiviral drug.

 -  Post-Liver Transplant Patients. ـPatients with primary haematological abnormalities
 not related to chronic hepatitis C virus infection

 -  Experienced patients (previously failed treatment)